Daniel W. Clarke, Ph.D.

Dan represents clients in the life sciences and hospital industries, including world-renowned cancer institutions and large health care systems. He focuses on intellectual property law, including patent application preparation and international prosecution.

He has experience in a wide spectrum of life sciences technologies, including immunology (antibodies and chimeric antigen receptor T cells), microbiology (probiotics and recombinant bacteria), genetics (gene editing and RNAi), oncology (immune checkpoint inhibitors and antigen-targeted nanoparticles), molecular diagnostics (biomarkers for disease detection and evaluation), molecular biology (next-generation sequencing and single-cell analysis systems), medical devices (biologically enhanced scaffolds and microfluidics), tissue and cell engineering/regeneration (stem cell technologies), and small molecule therapeutics (new chemical entities for treatment of various diseases), among many others.

Dan also advises clients on performing due diligence evaluations of intellectual property portfolios, including patentability, invalidity, non-infringement, and freedom-to-operate (FTO) analyses. He works with a broad range of clients, including academic institutions, small biotech start-ups, and large pharmaceutical companies, as well as the licensees of these organizations’ intellectual property rights